UNSPSC 51421801: Rofleponide

This classification denotes a therapeutic glucocorticoid with the molecular formula C25H34F2O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R9IQ7GVL3E, chemically known as 6 alpha, 9-difluoro-11 beta, 16 alpha, 17,21-tetrahydroxypregn-4-ene-3,20-dione, cyclic (r)-16,17-acetal with butyraldehyde. but generally known as rofleponide, which bears US NIH Compound Identifier 3055174. European Medicines Agency schedules Rofleponide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10357MIG.

UNSPSC 51421801 Rofleponide is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent activity shows the code being applied to broader emergency medical supply categories including naloxone and drug deactivation systems. State and local governments use this code to source pharmaceutical inventory for community health initiatives, emergency response programs, and public health departments. Issuing bodies include county health departments and community health organizations operating at the municipal level, which manage ongoing procurement for health-related supplies and medications.

Seminole County, Florida posted an IFB (IFB60459723LAS) on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, requiring quarterly deliveries to the Seminole County Community Health Building in Sanford. The contract structure includes an initial two-year term with a one-year renewal option, fixed-fee pricing, and standard compliance requirements including drug-free workplace certification, E-Verify authorization, and commercial general liability insurance. Recent activity in this code appears limited to this single tracked opportunity in Florida; geographic spread and repeat-buyer patterns across multiple states cannot be determined from available data.